Radboud University Nijmegen Medical Centre, Institute for Genetic and Metabolic Disease, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Brain. 2010 Nov;133(11):3210-20. doi: 10.1093/brain/awq261. Epub 2010 Sep 17.
Cerebellar hypoplasia and slowly progressive ophthalmological symptoms are common features in patients with congenital disorders of glycosylation type I. In a group of patients with congenital disorders of glycosylation type I with unknown aetiology, we have previously described a distinct phenotype with severe, early visual impairment and variable eye malformations, including optic nerve hypoplasia, retinal coloboma, congenital cataract and glaucoma. Some of the symptoms overlapped with the phenotype in other congenital disorders of glycosylation type I subtypes, such as vermis hypoplasia, anaemia, ichtyosiform dermatitis, liver dysfunction and coagulation abnormalities. We recently identified pathogenic mutations in the SRD5A3 gene, encoding steroid 5α-reductase type 3, in a group of patients who presented with this particular phenotype and a common metabolic pattern. Here, we report on the clinical, genetic and metabolic features of 12 patients from nine families with cerebellar ataxia and congenital eye malformations diagnosed with SRD5A3-congenital disorders of glycosylation due to steroid 5α-reductase type 3 defect. This enzyme is necessary for the reduction of polyprenol to dolichol, the lipid anchor for N-glycosylation in the endoplasmic reticulum. Dolichol synthesis is an essential metabolic step in protein glycosylation. The current defect leads to a severely abnormal glycosylation state already in the early phase of the N-glycan biosynthesis pathway in the endoplasmic reticulum. We detected high expression of SRD5A3 in foetal brain tissue, especially in the cerebellum, consistent with the finding of the congenital cerebellar malformations. Based on the overlapping clinical, biochemical and genetic data in this large group of patients with congenital disorders of glycosylation, we define a novel syndrome of cerebellar ataxia associated with congenital eye malformations due to a defect in dolichol metabolism.
脑小畸形和进行性眼疾是先天性糖基化障碍 I 型患者的常见特征。在一组病因不明的先天性糖基化障碍 I 型患者中,我们曾描述过一种特殊表型,其具有严重的早发性视力损害和各种眼部畸形,包括视神经发育不良、视网膜裂、先天性白内障和青光眼。一些症状与其他先天性糖基化障碍 I 型亚型的表型重叠,如蚓部发育不全、贫血、鱼鳞样皮炎、肝功能障碍和凝血异常。我们最近在一组具有这种特殊表型和共同代谢模式的患者中发现了编码类固醇 5α-还原酶 3 的 SRD5A3 基因突变。在此,我们报告了 9 个家系的 12 名患者的临床、遗传和代谢特征,这些患者被诊断为 SRD5A3-先天性糖基化障碍,其病因是类固醇 5α-还原酶 3 缺陷。该酶对于将多萜醇还原为 dolichol 是必需的,后者是内质网中 N-糖基化的脂质锚。Dolichol 合成是蛋白质糖基化的一个必要代谢步骤。目前的缺陷导致内质网中 N-聚糖生物合成途径的早期阶段糖苷化状态严重异常。我们在胎儿脑组织中检测到 SRD5A3 的高表达,尤其是在小脑,这与先天性小脑畸形的发现一致。基于这组大量先天性糖基化障碍患者重叠的临床、生化和遗传数据,我们定义了一种新的综合征,即小脑共济失调伴先天性眼畸形,其病因是 dolichol 代谢缺陷。